Curaleaf FY2024 EPS Forecast Decreased by Atb Cap Markets

Curaleaf Holdings, Inc. (OTCMKTS:CURLF) – Analysts at Atb Cap Markets cut their FY2024 earnings per share (EPS) estimates for Curaleaf in a note issued to investors on Thursday, November 7th. Atb Cap Markets analyst F. Gomes now expects that the company will post earnings per share of ($0.24) for the year, down from their prior forecast of ($0.21). The consensus estimate for Curaleaf’s current full-year earnings is ($0.24) per share. Atb Cap Markets also issued estimates for Curaleaf’s Q4 2024 earnings at ($0.04) EPS and FY2025 earnings at ($0.14) EPS.

Other equities research analysts have also recently issued research reports about the stock. Needham & Company LLC restated a “buy” rating and issued a $6.25 price target on shares of Curaleaf in a research report on Thursday, August 8th. Cormark downgraded shares of Curaleaf from a “moderate buy” rating to a “hold” rating in a report on Thursday.

Curaleaf Stock Performance

OTCMKTS:CURLF opened at $2.13 on Monday. The company has a market cap of $1.38 billion, a price-to-earnings ratio of -7.34 and a beta of 0.86. Curaleaf has a 1 year low of $2.07 and a 1 year high of $6.40. The stock’s 50 day simple moving average is $2.97 and its two-hundred day simple moving average is $3.79. The company has a debt-to-equity ratio of 0.83, a current ratio of 1.09 and a quick ratio of 0.50.

About Curaleaf

Curaleaf Holdings, Inc operates a cannabis operator in the United States. It operates through two segments, Domestic Operations and International Operations. The company offers flower, pre-rolls, flower pots, and dry-herb vaporizer cartridges; concentrates for vaporizing which includes pre-filled vaporizer cartridges and disposable vaporizer pens; and concentrates for dabbing, such as mints, distillate droppers, mints, topical balms and lotions, tinctures, lozenges, capsules, and edibles.